1. Home
  2. VERA vs XERS Comparison

VERA vs XERS Comparison

Compare VERA & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

N/A

Current Price

$29.79

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

XERS

Xeris Biopharma Holdings Inc.

N/A

Current Price

$10.42

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VERA
XERS
Founded
2016
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
VERA
XERS
Price
$29.79
$10.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
7
Target Price
★ $74.20
$12.86
AVG Volume (30 Days)
1.6M
★ 2.5M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 100.00
EPS
N/A
★ N/A
Revenue
N/A
★ $49,590,000.00
Revenue This Year
N/A
$32.91
Revenue Next Year
$841.44
$23.75
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 142.67
52 Week Low
$23.05
$5.25
52 Week High
$56.05
$11.42

Technical Indicators

Market Signals
Indicator
VERA
XERS
Relative Strength Index (RSI) 47.73 56.97
Support Level $26.38 $9.73
Resistance Level $36.95 $10.60
Average True Range (ATR) 1.58 0.48
MACD 0.19 -0.06
Stochastic Oscillator 58.65 41.25

Price Performance

Historical Comparison
VERA
XERS

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: